Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab added to (R)-GemOx for relapsed or progressed aggressive non-Hodgkin lymphoma in transplant-ineligible adults
2016-002272-27Phase 3Completed
- Sponsor
- Saarland University
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Saarland University. Primary endpoint: Progression-free survival. Started Jan 2017; status: completed.
02
Drugs
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2016-002272-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002272-27.